相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Potential Anti-cancer Drugs Commonly Used for Other Indications
Veronika Hanusova et al.
CURRENT CANCER DRUG TARGETS (2015)
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
Zhi-Jie Hou et al.
ONCOTARGET (2015)
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Martin Michaelis et al.
SCIENTIFIC REPORTS (2015)
Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer
Peter Nygren et al.
ACTA ONCOLOGICA (2014)
Development of other microtubule-stabilizer families: the epothilones and their derivatives
Cynthia F. Brogdon et al.
ANTI-CANCER DRUGS (2014)
Exploring the Potential of Flubendazole in Filariasis Control: Evaluation of the Systemic Exposure for Different Pharmaceutical Preparations
Laura Ceballos et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines
Vera Kralova et al.
ANTI-CANCER DRUGS (2013)
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Peter Nygren et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Cancer drug discovery by repurposing: teaching new tricks to old dogs
Subash C. Gupta et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Epigenetic and genetic features of 24 colon cancer cell lines
D. Ahmed et al.
ONCOGENESIS (2013)
Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012
L. Galluzzi et al.
CELL DEATH AND DIFFERENTIATION (2012)
Caspase-2 at a glance
Luca L. Fava et al.
JOURNAL OF CELL SCIENCE (2012)
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Irina Dobrosotskaya et al.
Endocrine Practice (2011)
Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs
Charles D. Mackenzie et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2011)
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Ren-Yuan Bai et al.
NEURO-ONCOLOGY (2011)
Albendazole sensitizes cancer cells to ionizing radiation
Kirtesh Patel et al.
RADIATION ONCOLOGY (2011)
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis
Mohammad H. Pourgholami et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Paul A. Spagnuolo et al.
BLOOD (2010)
Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole
Mohammad H. Pourgholami et al.
BMC CANCER (2010)
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer
Mohammad H. Pourgholami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Cellular Senescence in the Development and Treatment of Cancer
Gabriele Saretzki
CURRENT PHARMACEUTICAL DESIGN (2010)
Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells
Laureline Roger et al.
JOURNAL OF CELL SCIENCE (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The effectiveness of oracin in enhancing the cytotoxicity of doxorubicin through the inhibition of doxorubicin deactivation in breast cancer MCF7 cells
V. Hanusova et al.
XENOBIOTICA (2010)
An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe
S. Rello-Varona et al.
CELL DEATH & DISEASE (2010)
Inhibition of Cell Proliferation, Vascular Endothelial Growth Factor and Tumor Growth by Albendazole
Mohammad Hossein Pourgholami et al.
CANCER INVESTIGATION (2009)
Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target Effects
Yama A. Abassi et al.
CHEMISTRY & BIOLOGY (2009)
Microtubule Binding and Disruption and Induction of Premature Senescence by Disorazole C1
Marni Brisson Tierno et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Cancer cells display intra- and interline variation profound following prolonged exposure to antimitotic drugs
Karen E. Gascoigne et al.
CANCER CELL (2008)
Death through a tragedy: mitotic catastrophe
H. Vakifahmetoglu et al.
CELL DEATH AND DIFFERENTIATION (2008)
Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells
Nicole Doudican et al.
MOLECULAR CANCER RESEARCH (2008)
Caspase-2 is required for cell death induced by cytoskeletal disruption
L. H. Ho et al.
ONCOGENE (2008)
Epothilone-paclitaxel resistant leukemic cells CEWdEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways
Azita Khalilzadeh et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint
Daniela A. Brito et al.
CURRENT BIOLOGY (2006)
SW480, a p53 double-mutant cell line retains proficiency for some p53 functions
PJ Rochette et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype
YW Eom et al.
ONCOGENE (2005)
Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis
MH Pourgholami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Cell death by mitotic catastrophe: a molecular definition
M Castedo et al.
ONCOGENE (2004)
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy
M Castedo et al.
ONCOGENE (2004)
Endogenous p21WAF1/CIP1 status predicts the response of human tumor cells to wild-type p53 and p21WAF1/CIP1 overexpression
M Kralj et al.
CANCER GENE THERAPY (2003)
Pilot study of albendazole in patients with advanced malignancy - Effect on serum tumor markers/high incidence of neutropenia
DL Morris et al.
ONCOLOGY (2001)